Disease · MONDO_0100010

disease of the tendon

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. disease of the tendon. Diseases, record MONDO_0100010. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100010

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: disease of the tendon; Open Targets
Open Targets ID: MONDO_0100010; Open Targets
Other names: disease of tendon, disease or disorder of tendon, disorder of tendon, tendinopathy, tendon disease, tendon disease or disorder, tendonopathy, tendonosis; Open Targets
MeSH: D052256; MeSH
Highest stage of its drugs: Approval, for 5 of its 20 drugs, from DailyMed and FDA; Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LIDOCAINE	CHEMBL79	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
CAPSAICIN	CHEMBL294199	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
MENTHOL	CHEMBL256087	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
METHYL SALICYLATE	CHEMBL108545	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
NAPROXEN SODIUM	CHEMBL1200806	Small molecule	Approval	FDA	1	0	0	Drugs and targets
HYALURONIC ACID	CHEMBL5314376		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE DIPROPIONATE	CHEMBL1200384	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	11	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
IL17A	Interleukin-17A	1	Interleukin 17A inhibitor	Phase 3	https://conductscience.org/library/genes/3605	Drugs and targets
PTGS1	Cyclooxygenase	1	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	1	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6329	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05758415	Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy	Phase 3	60	2025-12-18	Rotator Cuff Tendinopathy	SECUKINUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05722522	Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy	Phase 3	33	2025-12-02	Rotator Cuff Tendinopathy	SECUKINUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT07434115	Orthobiological Therapies in Musculoskeletal Disorders	Early phase 1	300		Musculoskeletal Diseases or Conditions	HYALURONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT06376981	Hyaluronic Acid in Shoulder Tendinopathy	Phase 3	132		Shoulder Tendinitis	HYALURONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02867787	Study of the Treatment of Tendinopathy Unruptured of Rotator Cuff by Intramuscular Injection of Botulinum Toxin	Phase 2	40		Tendinopathy Rotator Cuff	ONABOTULINUMTOXINA	Open Targets' reading of its record	ClinicalTrials.gov
NCT00835939	Treatment for Achilles Tendinopathy	Phase 2/3	17		Achilles Tendinopathy, Achilles Tendon Enthesopathy, Mid-Portion Achilles Tendinopathy, Insertional Achilles Tendinopathy, Non-Insertional Achilles Tendinopathy	DEXTROSE, LIDOCAINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01111773	Study Evaluating a Heated Lidocaine and Tetracaine Topical Patch in the Treatment of Patients With Patellar Tendinopathy	Phase 2	13		Patellar Tendinopathy	LIDOCAINE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Secukinumab vs Placebo: deaths from any cause	0 of 30	0 of 30	60	NCT05758415	Trial comparisons
Secukinumab vs Placebo: serious adverse events	0 of 30	0 of 30	60	NCT05758415	Trial comparisons
Secukinumab vs Placebo: deaths from any cause	0 of 17	0 of 16	33	NCT05722522	Trial comparisons
Secukinumab vs Placebo: serious adverse events	0 of 17	1 of 16	33	NCT05722522	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0100010

GET https://conductscience.org/api/diseases/v1/MONDO_0100010/drugs

API reference For AI assistants